Updated:
Mingtai Pharmaceutical Investment
Mingtai Pharmaceutical Investment runs a dual-structure healthcare portfolio from Taizhou, China, combining direct venture deals with fund-of-funds commitments.
Mingtai Pharmaceutical Investment
Mingtai Pharmaceutical Investment is a private equity firm based in Taizhou, China. It focuses on venture capital investments.
General information
Firm type
Private Equity
Location
Region
Asia
Country
China
City
Taizhou
Corporate office
Taizhou, China
Sector focus
Frequently asked questions
What is Mingtai Pharmaceutical Investment's investment strategy?
The firm deploys a two-layered strategy within the pharmaceutical and healthcare sectors. It makes direct venture capital investments across seed, start-up, and general venture stages, and operates a parallel fund-of-funds program that commits capital to external healthcare-specialist fund managers. This structure combines concentrated single-company bets with diversified exposure through third-party funds.
Who runs investment decisions at Mingtai Pharmaceutical Investment?
The firm does not publicly name its principals, investment committee members, or senior deal leads on a website or LinkedIn presence. For a healthcare-first fund in China, verifying the scientific or clinical-operating background of the decision-makers — and whether they come from pharma R&D, regulatory bodies, or pure finance — is a basic threshold item for any institutional allocator or co-investor.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: